Sammenlign metoder
Gennemgå dine valgte metoder side om side; rækker, der afviger, er fremhævet.
| Adaptivt laboratorieeksperiment× | Adaptivt randomiseret kontrolleret forsøg× | |
|---|---|---|
| Fagområde | Forsøgsdesign | Forsøgsdesign |
| Familie | Process / pipeline | Process / pipeline |
| Oprindelsesår≠ | 1947 (sequential analysis foundations); adaptive laboratory applications widespread from 1990s | 1980s–2000s (formalized; earlier sequential testing roots from Wald, 1947) |
| Ophavsperson≠ | Rooted in sequential analysis (Abraham Wald, 1947); adaptive clinical/lab designs formalized by Berry and colleagues (1990s–2000s) | Donald Berry and others; foundational adaptive trial methods developed through 1980s–2000s biostatistics literature |
| Type≠ | Adaptive experimental design | Experimental design — adaptive variant of RCT |
| Oprindelig kilde≠ | Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36. DOI ↗ | Chow, S.-C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman & Hall/CRC. ISBN: 978-1584887690 |
| Aliasser | adaptive lab experiment, sequential adaptive laboratory study, response-adaptive laboratory design, adaptive experimental laboratory design | Adaptive RCT, Response-adaptive RCT, Adaptive clinical trial, Platform trial |
| Relaterede≠ | 5 | 6 |
| Resumé≠ | An adaptive laboratory experiment is a controlled experimental design conducted in a laboratory setting where pre-specified decision rules allow modifications to the study — such as sample size, treatment allocation, or stopping criteria — based on accumulating data. Unlike fixed designs, adaptive designs incorporate planned interim analyses that permit the experiment to respond to emerging evidence while maintaining statistical validity and Type I error control. | An adaptive randomized controlled trial (adaptive RCT) is an experimental design in which pre-specified rules allow modifications to the trial while it is ongoing — such as changing allocation ratios, dropping underperforming arms, or stopping early for efficacy or futility — based on accumulating interim data. These adaptations are planned before the trial starts and governed by statistical rules to preserve Type I error control and validity. |
| ScholarGateDatasæt ↗ |
|
|